APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS

Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, Mcilraith M, Hu C, Edwards CJ, Birbara CA, Mease PJ (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Rheumatology Karger AG

Book Volume: 55 1

Pages Range: 33-34

Authors with CRIS profile

Georg Schett Lehrstuhl für Innere Medizin III

Involved external institutions

Toronto Western Hospital CA Canada (CA) University of California, San Diego US United States (USA) (US) University of Sheffield GB United Kingdom (GB) Complejo Hospitalario Universitario de Santiago de Compostela ES Spain (ES) Schön Klinik Hamburg Eilbek DE Germany (DE) University of Genova / Università degli Studi di Genova IT Italy (IT) University of Orléans / Université d'Orléans FR France (FR) Celgene Corporation US United States (USA) (US) University Hospital Southampton NHS GB United Kingdom (GB) University of Massachusetts Amherst (UMass) US United States (USA) (US) Swedish Medical Center US United States (USA) (US)

How to cite

APA:

Gladman, D.D., Kavanaugh, A., Adebajo, A.O., Gomez-Reino, J.J., Wollenhaupt, J., Cutolo, M.,... Mease, P.J. (2016). APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS. (pp. 33-34).

MLA:

Gladman, Dafna D., et al. "APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS." 2016. 33-34.

BibTeX: Download